Healio

Trial of acoramidis for transthyretin amyloid cardiomyopathy misses primary endpoint

Please provide your email address to receive an email when new articles are posted on . In the 12-month topline results of the ATTRibute-CM trial, acoramidis, a treatment for symptomatic transthyretin ...

Omnissa Ranks Highest Across All Four Use Cases in the Gartner® Critical Capabilities for Endpoint Management Tools Report

Omnissa today announced it has been named a Leader in the inaugural 2026 Gartner® Magic Quadrant™ for Unified Endpoint Management (UEM) Tools and ranked the highest across all four Use Cases in the ...
Nasdaq

BridgeBio Announces ATTRibute-CM Month 12 Primary Endpoint Miss; Shares Plunge 72%

Nasdaq listed BridgeBio Pharma, Inc. (BBIO) has revealed Month 12 topline results from the Phase 3 ATTRibute-CM study. Following the results, shares of the biopharmaceutical company crashed 72% on ...
Healio

VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints

Please provide your email address to receive an email when new articles are posted on . Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that ...
Nasdaq

Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in ...
Virtualization Review

5 Attributes to Look for in Your VDI Client

Whether you're using an on-premises or off-premises VDI solution, there are specific qualities to consider when selecting an endpoint client for your users. I recently had a chance to work with zero, ...